+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate-Specific Membrane Antigen Inhibitor Market - Global Forecast 2026-2032- Product Image
Prostate-Specific Membrane Antigen Inhibitor Market - Global Forecast 2026-2032- Product Image
Sale

Prostate-Specific Membrane Antigen Inhibitor Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6127103
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Prostate-Specific Membrane Antigen Inhibitor Market is projected to reach USD 704.67 Million in 2026. It is expected to continue growing at a CAGR of 3.53%, reaching USD 876.32 Million by 2032.

PSMA Inhibitors: Executive Overview of a Precision Oncology Field

Prostate-specific membrane antigen (PSMA) inhibitors are radioligand and imaging agents designed to bind PSMA, a cell-surface protein expressed at high levels in many prostate cancers. The field is advancing through the integration of molecular imaging, patient selection, targeted radiation, and treatment monitoring. Clinical adoption depends on demonstrated patient benefit, regulatory authorization, production capacity, radiation-safety infrastructure, and access to specialized nuclear medicine services.

From Diagnostic Localization to Targeted Treatment Pathways

The landscape is shifting from standalone diagnostic imaging toward coordinated theranostic pathways, in which PSMA expression is first assessed through molecular imaging and then used to guide targeted treatment. This transition is increasing the importance of standardized imaging interpretation, dosimetry, multidisciplinary decision-making, and longitudinal monitoring. Evidence generation is also moving beyond late-stage disease toward earlier treatment settings, while developers and health systems address renal, hematologic, salivary-gland, and other safety considerations.

Artificial Intelligence Strengthens Imaging, Selection, and Operations

Artificial intelligence can support PSMA inhibitor workflows by improving lesion detection, image segmentation, disease quantification, and response assessment. Algorithms may also help harmonize interpretation across imaging centers and identify patients likely to benefit from treatment. However, clinical value depends on representative training data, external validation, transparent performance reporting, cybersecurity, and integration into radiology and nuclear medicine systems. Human oversight remains essential for eligibility decisions, safety review, and interpretation of atypical findings.

Regional Insights: Uneven Readiness Across Six Geographies

North America benefits from established oncology networks, advanced PET and radioligand infrastructure, and comparatively strong clinical-trial capacity, although reimbursement and facility access remain important constraints. Europe is shaped by coordinated regulatory and health-technology assessment processes, with variation among national payment systems and nuclear medicine capacity. Asia-Pacific combines sophisticated capabilities in countries such as Japan, Australia, and South Korea with substantial access differences across the region. Latin America faces infrastructure, reimbursement, and isotope-supply challenges, while Mexico and Brazil remain important clinical and regulatory environments. The Middle East is expanding tertiary-care and precision-oncology capacity, particularly in Gulf states, whereas Africa requires greater investment in imaging availability, radiopharmacy, workforce development, and referral networks.

Group Insights: Policy Alignment and Infrastructure Define Adoption

ASEAN markets show diverse regulatory pathways and uneven access to PET imaging, radiopharmacy, and specialist care. BRICS economies offer substantial patient populations and scientific capacity but differ widely in reimbursement, manufacturing, isotope logistics, and treatment availability. The European Union emphasizes cross-border standards, evidence assessment, and coordinated regulation, while G7 countries generally possess mature research and clinical infrastructure. GCC members are investing in advanced oncology services and centralized specialist capabilities. NATO countries span highly developed and emerging health systems, making interoperability, supply resilience, and shared clinical standards important considerations for regional implementation.

Country Insights: Distinct Regulatory and Clinical Priorities

The United States and Canada have strong theranostic research and specialist infrastructure, with access shaped by authorization, reimbursement, and radiopharmacy capacity. In Europe, France, Germany, Italy, Spain, and the United Kingdom combine substantial oncology expertise with differing assessment, procurement, and service-delivery models. Australia and Japan have advanced nuclear medicine capabilities, while South Korea is strengthening precision-oncology adoption and domestic technical capacity. China and India are expanding imaging, radiopharmaceutical, and clinical-research ecosystems, although access remains heterogeneous. Brazil and Mexico are key Latin American markets with growing specialist networks but continued infrastructure and affordability constraints. Russia maintains relevant scientific and clinical capabilities, while sanctions, supply conditions, and international connectivity may affect access to equipment, isotopes, and collaboration.

Action Priorities for Leaders Building Scalable PSMA Care

Industry leaders should prioritize evidence that links PSMA imaging and treatment to meaningful clinical outcomes, while clearly defining patient-selection criteria and safety-monitoring protocols. Partnerships with nuclear medicine centers can help expand trained workforces, dosimetry expertise, isotope access, and compliant handling capacity. Organizations should design region-specific access models that account for reimbursement, referral patterns, and infrastructure maturity rather than assuming uniform adoption. Investment in validated AI tools, interoperable data systems, resilient supply chains, and patient education can improve workflow efficiency without compromising clinical governance. Early engagement with regulators and health-technology assessors can also reduce uncertainty around evidence requirements and implementation.

Research Methodology: Evidence-Led Assessment of the PSMA Inhibitor Landscape

This executive summary uses a structured qualitative assessment of the PSMA inhibitor field, organized around technology evolution, clinical workflow, artificial intelligence, geography, policy groupings, and country-level readiness. The analysis considers publicly established characteristics of PSMA biology, molecular imaging, radioligand treatment, regulatory evaluation, nuclear medicine infrastructure, reimbursement, workforce requirements, and supply-chain conditions. Findings are framed as directional insights rather than quantitative market claims. Country and group comparisons reflect differences in health-system organization and implementation conditions, and should be validated against current regulatory decisions, clinical guidelines, local reimbursement rules, and facility-level data before operational use.

Conclusion: Coordinated Evidence and Infrastructure Will Shape Progress

PSMA inhibitors are advancing precision oncology by linking molecular characterization with targeted intervention, but clinical impact will depend on more than therapeutic performance alone. Consistent imaging, qualified personnel, reliable isotope and radiopharmacy systems, appropriate reimbursement, and robust safety governance are central to sustainable adoption. Regional and national conditions vary substantially, creating opportunities for tailored implementation strategies. Leaders that combine rigorous evidence generation with scalable service design, responsible AI, and equitable access planning will be best positioned to translate PSMA-directed care into routine clinical practice.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Prostate-Specific Membrane Antigen Inhibitor Market, by Molecule Type
7.1. Introduction
7.2. Monoclonal Antibody
7.2.1. Chimeric
7.2.2. Humanized
7.3. Small Molecule
7.3.1. Phosphoramidate
7.3.2. Urea-Based
8. Prostate-Specific Membrane Antigen Inhibitor Market, by Cancer Stage
8.1. Introduction
8.2. Advanced
8.3. Localized
8.4. Metastatic
9. Prostate-Specific Membrane Antigen Inhibitor Market, by Treatment Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line And Beyond
10. Prostate-Specific Membrane Antigen Inhibitor Market, by Administration Route
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Prostate-Specific Membrane Antigen Inhibitor Market, by Patient Age Group
11.1. Introduction
11.2. 65 To 74
11.3. 75 And Above
11.4. Under 65
12. Prostate-Specific Membrane Antigen Inhibitor Market, by Application
12.1. Introduction
12.2. Diagnostic Imaging
12.2.1. Pet Imaging
12.2.2. Spect Imaging
12.3. Therapeutic Treatment
12.3.1. Radioligand Therapy
12.3.1.1. Radiohalogen Conjugate
12.3.1.2. Radiometal Conjugate
12.3.2. Small Molecule Therapy
13. Prostate-Specific Membrane Antigen Inhibitor Market, by End User
13.1. Introduction
13.2. Cancer Treatment Centers
13.2.1. Private
13.2.2. Public
13.3. Diagnostic Laboratories
13.4. Hospital Pharmacies
13.5. Research Institutes
14. Prostate-Specific Membrane Antigen Inhibitor Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. Prostate-Specific Membrane Antigen Inhibitor Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. Prostate-Specific Membrane Antigen Inhibitor Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Blue Earth Diagnostics Ltd
18.2. Cardinal Health, Inc.
18.3. Curium US LLC
18.4. Eckert & Ziegler AG
18.5. ITM Isotope Technologies Munich SE
18.6. Lantheus Holdings, Inc.
18.7. Novartis AG
18.8. Pfizer Inc.
18.9. RayzeBio, Inc.
18.10. Siemens Healthineers AG
18.11. Telix Pharmaceuticals Limited
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global Prostate-Specific Membrane Antigen Inhibitor Market, Years Considered for the Study
FIGURE 2. Global Prostate-Specific Membrane Antigen Inhibitor Market, Research Design
FIGURE 3. Global Prostate-Specific Membrane Antigen Inhibitor Market, Research Framework
FIGURE 4. Global Prostate-Specific Membrane Antigen Inhibitor Market, Data Triangulation
FIGURE 5. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2025 vs 2032 (%)
FIGURE 7. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2025 vs 2032 (%)
FIGURE 9. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2025 vs 2032 (%)
FIGURE 11. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 13. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 15. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2025 vs 2032 (%)
FIGURE 17. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2025 vs 2032 (%)
FIGURE 19. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Prostate-Specific Membrane Antigen Inhibitor Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Prostate-Specific Membrane Antigen Inhibitor Market Segmentation & Coverage
TABLE 2. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 3. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 4. Global Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Monoclonal Antibody Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Chimeric Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Chimeric Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Chimeric Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Humanized Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Humanized Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Humanized Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Small Molecule Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Small Molecule Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Small Molecule Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Phosphoramidate Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Phosphoramidate Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Phosphoramidate Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Urea-Based Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Urea-Based Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Urea-Based Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 23. Global Advanced Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Advanced Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Advanced Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Localized Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Localized Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Localized Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Metastatic Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Metastatic Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Metastatic Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 33. Global First Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global First Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global First Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Second Line Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Second Line Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Second Line Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Third Line And Beyond Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Third Line And Beyond Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Third Line And Beyond Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 43. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 50. Global 65 To 74 Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global 65 To 74 Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global 65 To 74 Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global 75 And Above Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global 75 And Above Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global 75 And Above Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Under 65 Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Under 65 Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Under 65 Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 60. Global Diagnostic Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Diagnostic Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Diagnostic Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Pet Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Pet Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Pet Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Spect Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Spect Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Spect Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Therapeutic Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Therapeutic Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Therapeutic Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Radioligand Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Radioligand Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Radioligand Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Radiohalogen Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Radiohalogen Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Radiohalogen Conjugate Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Radiometal Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Radiometal Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Radiometal Conjugate Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Small Molecule Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Small Molecule Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Small Molecule Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 85. Global Cancer Treatment Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Cancer Treatment Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Cancer Treatment Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Private Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Private Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Private Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Public Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Public Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Public Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 118. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 120. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 121. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 122. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 123. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 124. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 125. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 126. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 127. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 128. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 129. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 130. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. North America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 132. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 134. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 135. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 136. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 137. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 138. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 139. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 140. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 141. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 142. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 143. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 144. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Latin America Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 146. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 148. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 149. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 150. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 151. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 152. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 153. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 154. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 155. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 156. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 157. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 158. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. Europe Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 160. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 161. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 162. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 163. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 164. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 165. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 166. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 167. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 168. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 169. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 170. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 171. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 172. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. Middle East Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 174. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 175. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 176. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 177. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 178. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 179. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 180. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 181. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 182. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 183. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 184. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 185. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 186. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Africa Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 188. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 189. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 190. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 191. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 192. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 193. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 194. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 195. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 196. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 197. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 198. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 199. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 200. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 201. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. ASEAN Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 203. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 204. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 205. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 206. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 207. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 208. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 209. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 210. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 211. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 212. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 213. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 214. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 215. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. GCC Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 217. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 218. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 219. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 220. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 221. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 222. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 223. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 224. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 225. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 226. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 227. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 228. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 229. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. European Union Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 231. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 232. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 233. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 234. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 235. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 236. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 237. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 238. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 239. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 240. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 241. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 242. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 243. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. BRICS Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 245. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 246. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 247. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 248. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 249. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 250. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 251. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 252. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 253. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 254. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 255. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 256. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 257. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 258. G7 Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 259. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 260. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 261. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 262. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 263. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 264. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 265. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 266. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 267. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 268. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 269. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 270. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 271. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. NATO Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 273. Global Prostate-Specific Membrane Antigen Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 274. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 275. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 276. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 277. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 278. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 279. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 280. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 281. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 282. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 283. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 284. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 285. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 286. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 287. United States Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 288. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, 2017-2032 (USD Million)
TABLE 289. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Molecule Type, 2017-2032 (USD Million)
TABLE 290. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Monoclonal Antibody, 2017-2032 (USD Million)
TABLE 291. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Small Molecule, 2017-2032 (USD Million)
TABLE 292. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Stage, 2017-2032 (USD Million)
TABLE 293. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 294. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 295. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 296. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Application, 2017-2032 (USD Million)
TABLE 297. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Diagnostic Imaging, 2017-2032 (USD Million)
TABLE 298. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Therapeutic Treatment, 2017-2032 (USD Million)
TABLE 299. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Radioligand Therapy, 2017-2032 (USD Million)
TABLE 300. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. Canada Prostate-Specific Membrane Antigen Inhibitor Market Size, by Cancer Treatment Centers, 2017-2032 (USD Million)
TABLE 302.

Companies Mentioned

  • Blue Earth Diagnostics Ltd
  • Cardinal Health, Inc.
  • Curium US LLC
  • Eckert & Ziegler AG
  • ITM Isotope Technologies Munich SE
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Pfizer Inc.
  • RayzeBio, Inc.
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited

Related Topics

Related Reports

Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report 2026 - Product Image

Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Free Prostate-Specific Antigen Assay Kit Market - Global Forecast 2026-2032 - Product Image

Free Prostate-Specific Antigen Assay Kit Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Total Prostate Specific Antigen Assay Kit Market - Global Forecast 2026-2032 - Product Image

Total Prostate Specific Antigen Assay Kit Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Prostate Specific Antigen (PSA) Test Market Report 2026 - Product Image

Prostate Specific Antigen (PSA) Test Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Prostate Specific Antigen Test Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type - Product Image

Prostate Specific Antigen Test Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.